© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to November
oral pan-coronavirus antiviral, rev. covalent
Ph. III candidate for COVID-19 (300 mg BID)
from SARS-CoV-1 inhibitor (WO2005113580)
Pfizer Worldwide Research
1. This month’s cover molecule, Pfizer’s PF-07321332 (API of Paxlovid) is an oral, reversible covalent SARS-CoV-2 main protease inhibitor, which has been submitted to the FDA by Pfizer for emergency approval…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.